Zydus Lifesciences to raise up to INR 5,000 crores for growth

Zydus Lifesciences Limited is proposing to raise up to INR 5,000 crores through the issuance of eligible securities. This fundraising initiative, approved by the board of directors on November 6, 2025, aims to support organic and inorganic growth opportunities, capital expenditure for expansion, and the repayment or settlement of existing borrowings. The company intends to issue a combination of equity shares, non-convertible debentures with warrants, or other equity-based securities, in one or more tranches, to eligible investors. The issue will be conducted through various methods, including qualified institutions placement (QIP), rights issue, preferential allotment, or private placement, subject to regulatory approvals.

Shareholders will vote on this special resolution via a postal ballot, with remote e-voting commencing on Thursday, November 13, 2025, and closing on Friday, December 12, 2025. The "cut-off date" for determining eligible voters is Friday, November 7, 2025. Central Depository Services Limited (CDSL) will provide the remote e-voting facility, and Ashish Doshi, partner of SPANJ & Associates, has been appointed as the scrutinizer.

Funds raised, particularly through a QIP, will be utilized in accordance with applicable laws. Up to 25% of the funds may be used for general corporate purposes, and a SEBI-registered credit rating agency will monitor the utilization of proceeds for issues exceeding INR 100 crores. Securities allotted through QIP will have a lock-in period of one year, unless sold on a recognized stock exchange or as otherwise permitted by SEBI ICDR Regulations.